戻る
Regeneron Pharmaceuticals Reports Strong Q2 2025 Performance Driven by Key Product Growth and R&D Progress
戻る
株式ニュース
テーマ
Regeneron Pharmaceuticals Reports Strong Q2 2025 Performance Driven by Key Product Growth and R&D Progress
Regeneron Pharmaceuticals Reports Strong Q2 2025 Performance Driven by Key Product Growth and R&D Progress
Edgen Stock
·
Sep 27 2025, 13:17
共有先
共有先
リンクをコピー
ソース：
[1] Regeneron Stock: Strong R&D Pipeline Drives Growth Outlook (NASDAQ:REGN) | Seeking Alpha
[2] Regeneron Q2 2025 slides: revenue rebounds to $3.68B after Q1 miss - Investing.com
[3] Regeneron Stock: Strong R&D Pipeline Drives Growth Outlook (NASDAQ:REGN)
Edgen Stock·Sep 27 2025, 13:17Edgen Stock·Sep 27 2025, 13:17
Edgen Stock·Sep 27 2025, 13:17